Evidence map›Paper›PMID 34751272›Full record

ArticlemedRxiv : the preprint server for health sciences2021

SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II.

Priscilla S Briquez, Sherin J Rouhani, Jovian Yu, Athalia R Pyzer, Jonathan Trujillo, Haley L Dugan, Christopher T Stamper, Siriruk Changrob, Anne I Sperling, Patrick C Wilson and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Priscilla S BriquezPritzker School for Molecular Engineering, University of Chicago, Chicago, Illinois, USA.
Sherin J RouhaniDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Jovian YuDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Athalia R PyzerDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Jonathan TrujilloDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Haley L DuganDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, Illinois, USA.
Christopher T StamperDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, Illinois, USA.
Siriruk ChangrobDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, Illinois, USA.
Anne I SperlingCommittee on Immunology, University of Chicago, Chicago, Illinois, USA.
Patrick C WilsonDepartment of Medicine, Section of Rheumatology, University of Chicago, Chicago, Illinois, USA.
Thomas F GajewskiDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Jeffrey A HubbellPritzker School for Molecular Engineering, University of Chicago, Chicago, Illinois, USA.
Melody A SwartzPritzker School for Molecular Engineering, University of Chicago, Chicago, Illinois, USA.
University of Chicago · US

Funding

Developing an Oncology Workforce for the 21st Century - Renewal 01K12CA139160 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F., SMITH, SONALI · 2010 to 2024
$10.6M
BASIC RESEARCH TRAINING IN MEDICAL ONCOLOGYT32CA009566 · NCI · UNIVERSITY OF CHICAGO · PI OLUFUNMILAYO F. OLOPADE · 1987 to 2026
$10.5M
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interfaceR01CA253248 · NCI · UNIVERSITY OF CHICAGO · PI SWARTZ, MELODY ANN · 2021 to 2025
$2.8M
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01R01CA219304 · NCI · UNIVERSITY OF CHICAGO · PI SWARTZ, MELODY ANN · 2018 to 2022
$1.8M
NCI NIH HHS K12 CA139160NCI NIH HHS R01 CA219304NCI NIH HHS R01 CA253248NCI NIH HHS T32 CA009566
6 · The paper itself

Abstract

Patients infected with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can experience life-threatening respiratory distress, blood pressure dysregulation and thrombosis. This is thought to be associated with an impaired activity of angiotensin-converting enzyme-2 (ACE-2), which is the main entry receptor of SARS-CoV-2 and which also tightly regulates blood pressure by converting the vasoconstrictive peptide angiotensin II (AngII) to a vasopressor peptide. Here, we show that a significant proportion of hospitalized COVID-19 patients developed autoantibodies against AngII, whose presence correlates with lower blood oxygenation, blood pressure dysregulation, and overall higher disease severity. Anti-AngII antibodies can develop upon specific immune reaction to the SARS-CoV-2 proteins Spike or RBD, to which they can cross-bind, suggesting some epitope mimicry between AngII and Spike/RBD. These results provide important insights on how an immune reaction against SARS-CoV-2 can impair blood pressure regulation.

Identifiers

PMID34751272
PMCPMC8575143
OpenAlexW3211143465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.